Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.14 USD
Change Today -0.005 / -3.45%
Volume 8.0K
BTHE On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

boston therapeutics inc (BTHE) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/18/14 - $0.80
52 Week Low
05/15/15 - $0.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

boston therapeutics inc (BTHE) Related Businessweek News

No Related Businessweek News Found

boston therapeutics inc (BTHE) Details

Boston Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. It produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. The company’s lead product candidates include BTI-320, a non-systemic, carbohydrate based compound, which has completed a Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients; and IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes. It is also developing OxyFex for use as an oxygen delivery agent for ischemia and trauma, as well as for blood loss during surgery in veterinary medicine applications. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Manchester, New Hampshire.

7 Employees
Last Reported Date: 04/28/15
Founded in 2009

boston therapeutics inc (BTHE) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, T...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $98.4K
Compensation as of Fiscal Year 2014.

boston therapeutics inc (BTHE) Key Developments

Boston Therapeutics, Inc. to Present Data on BTI-320, its Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate to Manage Blood Glucose

Boston Therapeutics, Inc. will present data on BTI-320, its novel, non-systemic, non-hypoglycemic drug candidate to manage blood glucose, as a poster presentation at the 75th Annual Meeting of the American Diabetes Association being held in Boston, June 5th to the 9th. The researchers concluded that BTI-320 acts as a competitive inhibitor of enzymes, such as amylase, lactase, maltase, and sucrase among other key carbohydrate hydrolyzing enzymes BTI-320 is a non-systemic, non-hypoglycemic drug in a chewable tablet designed to be taken before meals in order to reduce post-meal rapid elevations of blood glucose in people who need to manage their blood sugar levels. BTI-320 is a proprietary drug to be taken before meals and works via the gastrointestinal tract to block the action of carbohydrate hydrolyzing enzymes. BTI-320 reduces blood glucose elevations from rapid excursions after a meal by reducing the glycemic load (the rush of absorbable glucose and fructose) from foods.

Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Boston Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $51,329 compared with $43,827 for the same period last year. Operating loss was $734,873 compared with $1,558,130 for the same period last year. Net loss was $676,287 or $0.02 basic and diluted compared with $1,566,423 or $0.04 basic and diluted for the same period last year. Revenue increase is primarily related to revenue generated through its marketing partnership with Benchworks SD, LLC.

Boston Therapeutics, Inc. announced delayed 10-Q filing

On 05/15/2015, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTHE:US $0.14 USD -0.005

BTHE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTHE.
View Industry Companies

Industry Analysis


Industry Average

Valuation BTHE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at